CPhI Online

- Market News

Recipharm invests in its pMDI valves production capacity

10 Nov 2020

Image source: Recipharm AB

The expansion will bolster the CDMO's offering by ensuring it can fulfil the forecasted increase in demand for respiratory devices.

Contract development and manufacturing organisation (CDMO) Recipharm has announced its intention to invest in its King’s Lynn, UK facility, which specialises in inhalation and nasal device development and manufacturing, under the brand Bespak by Recipharm.

The investment will expand the company’s pressurised metered dose inhaler (pMDI) valves production capacity and is set to come on stream in late 2021.

The investment follows the acquisition of Consort Medical earlier this year and the subsequent launch of Recipharm’s specialist medical device brand, Bespak by Recipharm.

According to Keyvan Djamarani, CEO of Bespak, the last few years has seen a significant increase in the demand for pMDI valves. It is against this backdrop that the company has decided to support this growth from its Kings Lynn operation.

"The investment is a great opportunity to translate our acquisition into new high-quality profitable business and accelerate growth within our Advance Delivery Systems segment,” commented Djamarani.

“This expansion will bolster our offering even further by ensuring we are able to fulfil the forecasted increase in demand for respiratory devices whilst enabling our development team to support customers in inhalation and nasal drug development. In parallel, we are offering support to customers in using new more environmentally friendly propellants in their pMDIs,” added Jean-François Hilaire, Executive Vice President, Strategy & Global Integration at Recipharm.

Read More

Related Content